tiprankstipranks
Kura Oncology reports inducement grants under Nasdaq listing rule
PremiumThe FlyKura Oncology reports inducement grants under Nasdaq listing rule
26d ago
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
PremiumPress Releases
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
2M ago
Kura Oncology reports first patient dosed in trial of KO-2806
PremiumThe Fly
Kura Oncology reports first patient dosed in trial of KO-2806
2M ago
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
PremiumPress ReleasesKura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
2M ago
Is KURA a Buy, Before Earnings?
PremiumPre-Earnings
Is KURA a Buy, Before Earnings?
2M ago
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
2M ago
Kura Oncology price target raised to $32 from $30 at Barclays
PremiumThe FlyKura Oncology price target raised to $32 from $30 at Barclays
3M ago
Syndax downgraded to Sector Perform from Outperform at Scotiabank
PremiumThe Fly
Syndax downgraded to Sector Perform from Outperform at Scotiabank
3M ago
Kura Oncology price target raised to $32 from $26 at Mizuho
PremiumThe Fly
Kura Oncology price target raised to $32 from $26 at Mizuho
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100